ClinicalTrials.gg
RecruitingNCT05362760MINERVAUpdated May 16, 2025

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

A Phase 4 interventional study of Abemaciclib + Aromatase Inhibitor and Abemaciclib + Fulvestrant in Hormone Receptor-positive Metastatic Breast Cancer and HER2-negative Metastatic Breast Cancer, sponsored by Prof. Wolfgang Janni. Recruiting at 54 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Prof. Wolfgang Janni · Phase 4, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Planned enrollment
9th of 55
300 · median 120
Started
2022
with 2 others
Phase 4
8 of 55
4 open now
Primary completion
2029-04
later than 25 of 33 live
Registered
37th of 55
by date

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 3 that started in 2022, is one of 8 in phase 4, reaches primary completion later than 25 of the 33 other live ones, and was the 37th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulvestrant in pre- and postmenopausal patients with metastatic hormone receptor positive HER2 negative breast cancer in the first line setting.

Side effect monitoring and patient reported outcomes will be captured using the web- and app-based CANKADO digital health application. Via this user-friendly tool the patients can document their therapy side effects (e.g. diarrhea) and outcomes on a day-to-day basis. The capturing of side effects using the digital health application will be done additionally to the regular AE documentation.

Furthermore, translational research objectives of this trial include the investigation of biomarkers (ct-DNA, germline DNA) to evaluate whether they can give insights into the reasons for response, intrinsic or acquired resistance to the combined endocrine

03

Conditions studied

  • Hormone Receptor-positive Metastatic Breast Cancer
  • HER2-negative Metastatic Breast Cancer

Browse trials for

Keywords

  • hormone receptor-positive
  • HER2-negative
  • locally advanced/metastatic breast cancer
  • abemaciclib
  • endocrine therapy
  • phase IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be included in the trial only if they meet all the following criteria:

  1. Have given written prior to any trial-specific procedures
  2. Are reliable, willing to be available for the duration of the trial and are willing to follow trial procedures
  3. Are female and aged ≥ 18 years
  4. Diagnosis of hormone receptor positive (HR+), - breast cancer. Although not required as a protocol procedure, disease should be considered for whenever possible to reassess HR and HER2 status if clinically indicated.
  5. To fulfill the requirement for HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (estrogen receptor [ER], progesterone receptor [PgR]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).
  6. To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP guidelines (Wolff et al. 2013).
  7. Have locally advanced recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
  8. Indication for endocrine based therapy in the metastatic setting
  9. Have a performance status (PS) of ≤2 on the (ECOG) scale
  10. If central nervous system (CNS) metastases are known these have to be stable (radiotherapy finished for more than 14 days ago, no required medication with more than 4 mg Dexamethasone per day)
  11. Pre- and patients are allowed. Postmenopausal is defined as no menses for 12 months without an alternative medical cause. Women of (WOCBP, defined as not postmenopausal and not surgically or congenitally sterile) whose male partners are potentially fertile (e.g. no vasectomy) must use highly effective methods for the duration of the trial and for at least 3 weeks after last dose of drugs used in the trial.Women of childbearing potential must use highly effective contraception methods for two years after the last dose of fulvestrant. Highly effective birth control methods that results in a failure rate of less than 1% per year include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. Sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the patient.
  12. No prior therapy for metastatic disease (except for endocrine therapy for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry)
  13. Previous endocrine therapy and (neo)adjuvant chemotherapy is allowed
  14. Patients who received chemotherapy must have recovered ( [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or ≤ Grade 2 peripheral neuropathy prior to registration. A of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy).
  15. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration.
  16. One of the following as defined by the v1. 1 (see Attachment 15.5):

    1. . At least one measurable lesion assessable using standard techniques by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1). Tumor evaluation according to RECIST version 1.1 (based on local assessment) has to be performed within 28 days before trial registration.
    2. Nonmeasurable bone-only disease (must be evaluable, but not necessarily measurable by RECIST). Nonmeasurable bone-only disease may include any of the following: blastic bone lesion, lytic bone lesions without a measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft tissue component.
  17. The patient has adequate bone marrow and organ function evidenced by the following laboratory results: (ANC) ≥ 1.5 × 109/L, count ≥ 100 × 109/L, ≥ 8 g/dL, (ALT) and aspartate aminotransferase (AST) ≤ 2.0 × (≤ 3 x ULN in case of liver metastases), Total ≤ 1.5 × ULN (with Gilbert's syndrome max. 2 x ULN), Serum Creatinine ≤ 2.0 mg/dl or 177µmol/L, Coagulation: (INR) ≤ 1,5
  18. The patient is able to swallow oral medications
  19. Willingness to use the provided CANKADO digital health application to report side effects and patient reported outcomes (The use of the CANKADO app is not mandatory for study participation, but is strongly recommended)
  20. Negative pregnancy test before trial registration for women of child-bearing potential and highly effective contraception if the risk of conception exists and a negative serum pregnancy test within 7 days after the first dose of trial treatment. Pregnancy tests should be performed in premenopausal patients according to local standard

Exclusion criteria

Exclusion Criteria:

Patients will be included in the trial only if they meet none of the following criteria:

  1. Visceral crisis or \< 6 months
  2. History of reactions attributed to Abemaciclib or to other components of drug formulation
  3. Prior treatment with chemotherapy in the setting or endocrine therapy in the metastatic setting (except for endocrine therapy in metastatic or locally advanced disease for maximal 3 months prior to start of abemaciclib therapy and if no progress occurred before study entry)
  4. Patient not eligible for endocrine based therapy
  5. Any concurrent severe, uncontrolled systemic disease, social or psychiatric condition that might interfere with the planned treatment and with the patient's adherence to the protocol
  6. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this trial (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated \<30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  7. Prior treatment with a CDK4/6 inhibitor for metastatic or locally advanced disease (first-line treatment with a CDK 4/6 inhibitor (Ribociclib/Palbociclib) in the metastatic setting is allowed only if terminated due to toxicity after max 3 months and no progression occurred before study entry. Prior treatment with a CDK 4/6 inhibitor in the neo-/ setting is allowed.)
    1. Treatment with any other agents within four weeks or 5 half-lives prior to trial registration, whichever is longer
  8. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  9. Females who are pregnant or lactating
  10. Legal incapacity or limited legal capacity
  11. History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.
  12. The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating trial treatment), fungal infection, or detectable viral infection (such as known positivity or with known active or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
  13. Prior systemic anti-cancer therapy within the last 21 days prior to start of trial treatment except for first-line endocrine therapy in metastatic or locally advanced disease (see above)
  14. Radiotherapy within the last 14 days prior to registration
  15. Patient has had major surgery within 14 days prior to trial registration.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Abemaciclib + Aromatase-Inhibitor

    The patients will receive Abemaciclib in combination with an Aromatase-Inhibitor (either Anastrozole, Letrozole or exemestane)

    Drug: Abemaciclib + Aromatase Inhibitor

  • Experimental
    Abemaciclib + Fulvestrant

    The patients will receive Abemaciclib in combination Fulvestrant

    Drug: Abemaciclib + Fulvestrant

Interventions

  • DrugAbemaciclib + Aromatase Inhibitor

    Drug pages: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Aromatase inhibitorsStudies of Aromatase inhibitorsAromatase inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)

    Also known as: Verzenios

  • DrugAbemaciclib + Fulvestrant

    Drug pages: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)

    Also known as: Verzenios

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS, defined as the time from date of trial registration until progressive disease (PD) or death from any cause, whichever comes first (as defined by RECIST guideline version 1.1). If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.

    Time frame: Time from date of trial registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary outcomes

  1. Adverse Events

    Adverse Events assessed by investigator (type, frequency, severity (graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0)), seriousness)

    Time frame: From obtaining informed consent until progressive disease (PD) or up to 30 days after end of trial treatment

  2. Patient-reported side effects

    Additional capture of Patient-Reported side effects on a daily basis via CANKADO PRO-React (patient diary).

    Time frame: From first dose of study medication up to 30 days after end of trial treatment

  3. Patient-reported global health status

    Daily self-assessment of global health status using the visual analogue scale (EQ-VAS, based on the EQ-5D questionnaire) via CANKADO. The EQ-VAS scale ranges from 0 (the worst possible health status to 100 (the best possible health status).

    Time frame: From first dose of study medication up to 30 days after end of trial treatment

  4. Frequency of hospitalizations

    Frequency of hospitalizations during study treatment

    Time frame: Time from date of registration for the trial through study completion (4 years after date of First Patient In)

  5. Patient reported European Organisation for Research and Treatment of Cancer Quality of Life C30 questionaire (EORTC QLQ-C30)

    Patient reported quality of life as assessed with the EORTC QLQ-C30 questionnaire. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline, at 3, 6, 9, 12, 18, 24 months

  6. Patient reported European Organisation for Research and Treatment of Cancer Quality of Life B23 breast cancer module questionaire (EORTC QLQ-BR23)

    Patient reported quality of life as assessed with the EORTC QLQ-BR23 questionnaire. The QLQ-B23 breast cancer module incorporates five multi-item scales to assess systemic therapy side effects, arm symptoms, breast symptoms, body image and sexual functioning. In addition, single items assess sexual enjoyment, hair loss and future perspective. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline, at 3, 6, 9, 12, 18, 24 months

  7. Clinical benefit rate (CBR)

    CBR defined as percentage of patients with complete response, partial response or stable disease

    Time frame: Time from date of registration for the trial until 24 weeks of study treatment

  8. Overall Survival (OS)

    Overall survival (OS) defined as the time from date of trial registration until date of death due to any cause. If a patient is not known to have died, survival is censored at the date of last contact.

    Time frame: Time from date of trial registration until date of death due to any cause, assessed up to 48 months

  9. Objective Response Rate (ORR)

    ORR defined as percentage of patients with complete or partial response as defined by RECIST 1.1

    Time frame: Time from date of registration for the trial through study completion (4 years after date of First Patient In)

  10. Number of patients with primary progression

    Number of patients with primary progression, defined as number of patients with disease recurrence within 12 weeks after recruitment.

    Time frame: Time from date of registration for the trial until first imaging after 12 weeks

07

Study locations

54 of 54 sites recruiting
  • Kliniken Ostalb gkAöR
    Aalen, Germany
    Recruiting
  • Klinikum St. Marien Kommunalunternehmen - AöR Der Stadt Amberg
    Amberg, Germany
    Recruiting
  • Klinikum Aschaffenburg-Alzenau gGmbH
    Aschaffenburg, Germany
    Recruiting
  • Gemeinschaftspraxis Dr. Heinrich / Dr. Bangerter
    Augsburg, Germany
    Recruiting
  • Universitätsklinikum Augsburg A.d.ö.R
    Augsburg, Germany
    Recruiting
  • MediOnko-Institut GbR
    Berlin, Germany
    Recruiting
  • Hämatologikum Biberach
    Biberach, Germany
    Recruiting
  • Gynäkologisches Zentrum Bonn - Friedensplatz
    Bonn, Germany
    Recruiting
  • Studien GbR Braunschweig
    Braunschweig, Germany
    Recruiting
  • Hämato-Onkologische Praxis im Medicum
    Bremen, Germany
    Recruiting
  • Onkologisches Zentrum Donauwörth
    Donauwörth, Germany
    Recruiting
  • Gemeinschaftspraxis
    Dresden, Germany
    Recruiting
  • Onkozentrum Dresden
    Dresden, Germany
    Recruiting
  • MVZ Medical Center Düsseldorf GmbH
    Düsseldorf, Germany
    Recruiting
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
    Recruiting
  • Internistische Praxis Ehingen
    Ehingen, Germany
    Recruiting
  • Universitätsklinikum Erlangen
    Erlangen, Germany
    Recruiting
  • St. Antonius-Hospital
    Eschweiler, Germany
    Recruiting
  • Centrum für Hämatologie und Onkologie Bethanien
    Frankfurt, Germany
    Recruiting
  • Universitätsklinikum Freiburg
    Freiburg, Germany
    Recruiting
  • Krankenhäuser Landkreis Freudenstadt gGmbH
    Freudenstadt, Germany
    Recruiting
  • Internistische Gemeinschaftspraxis
    Friedrichshafen, Germany
    Recruiting
  • Klinikum Garmisch-Partenkirchen GmbH
    Garmisch-Partenkirchen, Germany
    Recruiting
  • Main-Kinzig-Kliniken gGmbH Gelnhausen
    Gelnhausen, Germany
    Recruiting
  • Gemeinschaftspraxis und Tagesklinik Halle
    Halle, Germany
    Recruiting
  • Albertinen-Krankenhaus
    Hamburg, Germany
    Recruiting
  • Sana Klinikum Hameln-Pyrmont
    Hameln, Germany
    Recruiting
  • Frauenärzte am Bahnhofsplatz
    Hildesheim, Germany
    Recruiting
  • ViDia Christliche Kliniken Karlsruhe
    Karlsruhe, Germany
    Recruiting
  • Klinikum Kassel GmbH
    Kassel, Germany
    Recruiting
  • Klinikverbund Kempten-Oberallgäu gGmbH
    Kempten, Germany
    Recruiting
  • Klinikum Konstanz
    Konstanz, Germany
    Recruiting
  • ZAGO- Zentrum für ambulante gynäkologische Onkologie
    Krefeld, Germany
    Recruiting
  • St. Elisabeth-Krankenhaus GmbH
    Köln, Germany
    Recruiting
  • Krankenhausgesellschaft St. Vincenz mbH
    Limburg, Germany
    Recruiting
  • Kliniken Ostalb gkAöR, Stauferklinikum Schwäbisch Gmünd
    Mutlangen, Germany
    Recruiting
  • Praxis für gynäkologische Onkologie / Prof. Dr. med. Ulrike Nitz / Raquel von Schumann
    Mönchengladbach, Germany
    Recruiting
  • LMU - Klinikum der Universität München
    München, Germany
    Recruiting
  • München Klinik gGmbH Harlaching
    München, Germany
    Recruiting
  • TZN-Tumorzentrum Niederrhein GmbH
    Neuss, Germany
    Recruiting
  • Klinikum Nürnberg Nord
    Nürnberg, Germany
    Recruiting
  • medius KLINIK NÜRTINGEN
    Nürtingen, Germany
    Recruiting
  • Praxis Dr. Guth
    Plauen, Germany
    Recruiting
  • Klinikum Ernst von Bergmann gGmbH
    Potsdam, Germany
    Recruiting
  • Klinikum Rheine
    Rheine, Germany
    Recruiting
  • GPR Gesundheits- und Pflegezentrum Rüsselsheim gGmbH
    Rüsselsheim, Germany
    Recruiting
  • Diakoneo Diak-Klinikum Schwäbisch Hall gGmbH
    Schwäbisch Hall, Germany
    Recruiting
  • Clinical Research Stolberg GmbH
    Stolberg, Germany
    Recruiting
  • Gynäkologie Kompetenzzentrum Stralsund
    Stralsund, Germany
    Recruiting
  • Universitätsfrauenklinik Tübingen
    Tübingen, Germany
    Recruiting
  • University Hospital Ulm Gynecology/Obstetrics
    Ulm, Germany
    Recruiting
  • St. Josefs-Hospital
    Wiesbaden, Germany
    Recruiting
  • Spital Wallis
    Brig, Switzerland
    Recruiting
  • Kantonsspital St. Gallen
    Saint Gallen, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2029, 84 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 84 months is above that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
May 5, 2022
StartActual
Apr 27, 2022
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05362760
Lead sponsor
Prof. Wolfgang Janni
Responsible party
Prof. Wolfgang Janni (Director of the Department of Obstetrics and Gynecology, University of Ulm) — Sponsor-investigator
First posted
May 5, 2022
Start date
Apr 27, 2022
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
May 16, 2025

Study contacts

Natalie Uhl
Contact
natalie.uhl@uniklinik-ulm.de
+49 731 500 58652
Brigitte Rack, Prof. Dr.
principal investigator · Department of Gynecology and Obstetrics, University Hospital Ulm, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Aromatase inhibitors · Fulvestrant

Start the discussion